News

April 13, 2020April 13, 2020

Bristol Myers, Bluebird Bio Seek FDA Approval of Ide-cel to Treat Advanced Multiple Myeloma

News

Bristol Myers Squibb and Bluebird Bio are seeking U.S. approval of their lead investigational CAR T-cell therapy — idecabtagene vicleucel (ide-cel; bb2121) — for the treatment of heavily pre-treated ... Read more

April 6, 2020April 14, 2020

Melflufen Shows Positive Response in Triple-refractory Multiple Myeloma Trial

News

Topline results show a 26% response rate in a Phase 2 clinical trial evaluating melflufen (melphalan flufenamide) in patients with triple-refractory multiple myeloma, a difficult-to-treat form of this disease, the ... Read more

March 30, 2020April 14, 2020

Oncopeptides’ Accelerated Approval Filing for Melflufen in US Unimpeded by COVID-19

News

Despite some interruptions to melflufen‘s (melphalan flufenamide) clinical program due to the ongoing COVID-19 outbreak, Oncopeptides‘ application seeking its accelerated approval in the U.S. for the treatment of triple-refractory ... Read more

March 23, 2020March 23, 2020

Genetic Test May Help Identify Ultra High-risk Multiple Myeloma

News

A novel genetic test could help identify people with multiple myeloma who are at highest risk of aggressive disease and unlikely to respond to standard treatment with Revlimid (lenalidomide), ... Read more

March 20, 2020March 20, 2020

Ninlaro Combo Fails to Extend New Myeloma Patients’ Survival Without Disease Worsening

News

A combination of Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone failed to significantly extend the time to disease progression or death in people with newly diagnosed multiple myeloma who are ineligible ... Read more

March 18, 2020March 23, 2020

FDA Names Arcellx’s Cell Therapy CART-ddBCMA Orphan Drug for Multiple Myeloma

News

Arcellx’s CART-ddBCMA — a CAR T-cell therapy targeting the BCMA protein — was granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of ... Read more

March 16, 2020March 16, 2020

Gains in 5-Year Survival with Stem Cell Transplant Evident Since Late ’90s

News

The long-term survival of people with multiple myeloma following autologous stem cell transplant has steadily improved since 1997 through with the introduction of new medicines, a large review study ... Read more

March 13, 2020March 23, 2020

Empliciti Combo Fails to Stem Progression of Newly Diagnosed Multiple Myeloma

News

Empliciti (elotuzumab), in combination with Revlimid (lenalidomide) and dexamethasone, did not significantly extend the time people with multiple myeloma lived without disease progression, compared with Revlimid and dexamethasone alone, ... Read more

March 11, 2020March 11, 2020

RRMM Trial Testing Safety, Efficacy of TAK-169 Therapy Doses First Patient

News

The first patient has been dosed in a Phase 1 clinical trial testing the safety and efficacy of the CD38-targeting therapy TAK-169 in people with relapsed or refractory multiple myeloma, ... Read more

March 10, 2020March 10, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

Pin It on Pinterest